A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age.
Phase of Trial: Phase II/III
Latest Information Update: 02 Dec 2011
At a glance
- Drugs MEDI 3250 (Primary) ; Influenza virus vaccine live
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors MedImmune
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2011 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 03 Aug 2009 New trial record